Kymera Therapeutics

KYMRNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$9.784 B

$117.67 -0.07%

Close of 21 Sept 2026

Revenue

$39.2M

#2808 by revenue

Earnings

$311.4M

#820 by earnings

Shares outstanding

83,150,618

Latest filing cover page

P/E ratio

31.4

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#12Twist BioscienceTWST$11.0B
#13Krystal BiotechKRYS$9.88B
#14Kymera TherapeuticsKYMR$9.78B
#15QiagenQGEN$9.23B
#16ImmunityBioIBRX$8.96B

What if Kymera Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.3T

$364,086.94

Per share 3,094× higher

Bitcoin $1.72T

$20,682.99

Per share 176× higher

Nvidia $5.48T

$65,902.79

Per share 560× higher

Or at a round number

$20.0B $50.0B $100.0B $200.0B

Where these numbers come from

Share counts and financials for Kymera Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.